Abbott Q3 adj EPS $1.14, rev $10.1B; raises FY23 EPS midpoint

ABBOTT LABORATORIES

2023-Q3 EPS reported $2.35 revenue$29,868,000,000

Q3 GAAP EPS $0.82; adjusted EPS $1.14; reported sales $10.1B (-2.6% YoY).
Organic base-business sales (ex-COVID tests) up 13.8%; double-digit growth in all four segments.
Full-year 2023 adjusted EPS guidance raised to $4.42–$4.46 (midpoint $4.44 vs prior $4.30–$4.50).
Medical Devices organic growth 14.7%; FreeStyle Libre sales $1.4B (+28.5% organic).
Quarterly dividend maintained at $0.51/share; 399th consecutive quarterly payout.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ABBOTT LABORATORIES updated its third quarter ended Sept. 30, 2023 guidance (raised).

Period: third quarter ended Sept. 30, 2023
Guidance: raised
Result: reported results

Exact text from the filing

Abbott today announced financial results for the third quarter ended Sept. 30, 2023. • Third-quarter GAAP diluted EPS of $0.82 and adjusted diluted EPS of $1.14, which excludes specified items. • Abbott narrowed its full-year 2023 EPS guidance range. Abbott projects full-year diluted EPS on a GAAP basis of $3.14 to $3.18 and projects adjusted diluted EPS of $4.42 to $4.46, which represents an increase at the midpoint of the guidance range.

View on SEC.gov

Browse all earnings releases →

ABBOTT LABORATORIES filing history →

Source: SEC EDGAR

accession 0001628280-23-034544

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.